The most striking cluster of recent filings comes from ESSITY B, the Swedish hygiene group. Industrivarden, an investment company with board representation, bought roughly $24M of shares across multiple tranches on August 24. Activist fund Cevian Capital added $34.9M in July. Together, those two names filed buys totalling nearly $62M. That level of coordinated buying from parties with genuine visibility into the business is a meaningful signal.
The sellers tell a different story at GLAND, India's injectable pharma exporter. Fosun Pharma Industrial, the Chinese promoter group, sold a combined $296M of Gland shares in early September, filing those disposals on September 8. The two tranches covered 9.9 million shares at around $30 apiece. Fosun has been reducing its India exposure for some time, and this is the largest single exit disclosed so far. Indian pharma export volumes are running strong, ORTEX Alt Data shows Indian auto export unit sales up 32% year on year in September 2026, a broader sign of Indian industrial health, which makes the Fosun retreat look like a China-side liquidity decision rather than a view on Gland's prospects.
In Georgia-focused banking, BGEO CEO Zurab Kokosadze filed a discretionary sale of 10,000 shares worth $1.84M on September 8. The trade date was September 4. The sale is open-market and carries no 10b5-1 label, making it a harder signal to dismiss.
The latest data in the vendor insider table is dated September 8. More recent US-market filings require direct SEC EDGAR access.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
